SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cameco Corp. engages in the provision of uranium. It operates through the Uranium and Fuel Services segments. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Cameco is trending as investors focus on uranium as the essential backbone for AI-driven energy demand, with ongoing community discussion centered on nuclear's role as a critical, long-term power source. Sentiment is further buoyed by major recent supply deals and consistent institutional rotation into the sector, with many traders looking for a breakout above key psychological resistance levels.

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

Evommune Inc.

Evommune Inc

Evommune is generating significant investor buzz following positive clinical trial data and the strategic expansion of its pipeline into migraine prophylaxis, a move that is reshaping the company's perception as a multi-therapeutic powerhouse. While some community members are focused on potential near-term catalysts and short-squeeze dynamics, others are actively debating the long-term efficacy of its drug candidates and the impact of executive stock activity.

SiTime Corp.is a micro-electromechanical system-based silicon timing solution. The company is transforming the timing industry with configurable solutions that replace legacy quartz devices and enable customers to differentiate their products with performance, smaller size, lower power, and reliability. The company was founded by Markus Lutz and Aaron Partridge on December 3, 2003 and is headquartered in Santa Clara, CA.

SiTime Corp

SiTime is trending as community members discuss its dominance in the precision timing market and its critical role in AI data center infrastructure. Investors are closely monitoring its volatile technical patterns and recent supply chain developments while debating the stock's valuation versus its long-term potential as a monopoly-like leader.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

Dash is experiencing heightened interest as part of a broader resurgence in privacy-focused tokens, with community members actively comparing it to Zcash and Monero while watching for potential breakouts. Traders are closely monitoring the asset's technical patterns and integration news, expressing optimism that increased volume and adoption will drive momentum despite recent market volatility.

NexGen Energy Ltd. engages in the acquisition, exploration and development of uranium properties. Its uranium project portfolio includes Arrow, South Arrow, Harpoon, Bow, IsoEnergy, SW1, SW2, SW3, and IsoEnergy properties. The company was founded by Leigh B. Curyer on March 8, 2011 and is headquartered in Vancouver, Canada.

NexGen Energy Ltd

NexGen Energy is trending as institutional and retail investors focus on the company's tier-one Rook I project, which is seen as a critical asset for addressing the tightening global uranium supply deficit. The community is actively discussing the stock's potential for federal permitting approval and its strategic value for meeting the surging power needs of AI data centers.

Flex Ltd. operates as a manufacturing services company. It delivers technology innovation, supply chain, and manufacturing solutions to diverse industries and end markets. The firm operates through the following segments: Integrated Technology Solutions (ITS), Regulated Manufacturing Solutions (RMS) and Cloud and Power Infrastructure (CPI). The Integrated Technology Solutions segment consists of Communications, including high speed networking, enterprise, and satellite communications systems Lifestyle, including premium products across commercial, home and personal product categories. The Regulated Manufacturing Solutions segment consists of Industrial, including mission-critical automation, energy, and industrial infrastructure, Automotive, including compute and power electronics platforms, and integrated systems, Healthcare, including regulated manufacturing for medical devices, drug delivery and equipment. The Cloud and Power Infrastructure segment consists of Cloud and Cooling, including integrated compute systems supporting power-dense digital infrastructure deployments, and advanced liquid cooling solutions supporting higher-density, power-intensive rack architectures, Power, utility and facility-level, including electrical infrastructure enabling reliable, scalable power delivery and high-density rack- and board-level power systems supporting power-intensive compute workloads. The company was founded by Joe McKenzie and Barbara-Ann McKenzie in 1969 and is headquartered in Austin, TX.

Flex Ltd

Flex Ltd. is gaining investor attention following its official inclusion in the S&P 500, a move expected to trigger significant passive fund inflows. The market is also actively debating the company's long-term potential as it shifts toward a specialized AI infrastructure focus, particularly ahead of a planned spin-off of its Cloud and Power Infrastructure business.

Viper Energy, Inc. engages in the acquisition of oil and natural gas properties. It owns, acquires, and exploits oil and natural gas properties in North America. The company was founded on September 18, 2013 and is headquartered in Midland, TX.

Viper Energy Inc - Ordinary Shares - Class A

Viper Energy Partners LP

Viper Energy Partners is trending as investors monitor its strategic Permian Basin position and recent merger activities against a backdrop of global energy supply concerns. The community is actively discussing the stock's dividend potential and the long-term impact of its expanded asset footprint within the energy sector.

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry and to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The company was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in 1990 and is headquartered in New York, NY.

Schrodinger Inc

Schrodinger Inc. is trending as investors debate the potential of its AI-driven drug discovery platform while navigating concerns over capital-intensive proprietary programs and near-term revenue transitions. Community sentiment remains polarized, with some highlighting the stock's significant long-term potential as a 'multi-bagger' in the AI biotech gold rush, while others focus on management frustrations and the company's persistent cash-burning model.

GE Healthcare Technologies, Inc. engages in the development and manufacturing of medical technology, pharmaceutical diagnostics, and digital solutions. It operates through the following segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment provides scanning devices, clinical applications, service capabilities, and digital solutions. The AVS segment offers screening, diagnosis, treatment, and monitoring of certain diseases. The PCS segment specializes in providing medical devices, consumables, services, and digital solutions. The PDx segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company was founded in 1892. It was incorporated on May 16, 2022 and is headquartered in Chicago, IL.

GE HealthCare Technologies Inc

GE HealthCare is currently trending after receiving FDA 510(k) clearance for its AI-powered MIM Contour ProtegeAI+ 2.0 software, designed to streamline radiation oncology treatment planning. The stock remains a key topic of community discussion as investors weigh the potential of AI-driven medical innovation against ongoing debates regarding the company's valuation and the broader defensive sector rotation.

S&P Global, Inc. engages in the provision of transparent and independent ratings, benchmarks, analytics, and data to the capital and commodity markets worldwide. It operates through the following segments: Market Intelligence, Ratings, Mobility, Indices, and Engineering Solutions. The Market Intelligence segment provides multi-asset-class data and analytics integrated with purpose-built workflow solutions. The Ratings segment is involved in credit ratings, research, and analytics, offering investors and other market participants information, ratings, and benchmarks. The Mobility segment offers solutions serving the full automotive value chain including vehicle manufacturers, automotive suppliers, mobility service providers, retailers, consumers, and finance and insurance companies. The Engineering Solutions segment engages in advanced knowledge discovery technologies, research tools, and software-based engineering decision engines to advance innovation, maximize productivity, improve quality, and reduce risk. The company was founded by James H. McGraw and John A. Hill in 1917 and is headquartered in New York, NY.

S&P Global Inc

S&P Global is trending as investors rotate into high-quality, wide-moat compounders that are currently trading at significant discounts near 52-week lows. The community is actively debating the stock's long-term value, with many viewing the ongoing valuation contraction as a prime entry point for long-horizon capital while also monitoring the upcoming Mobility division spin-off as a key strategic catalyst.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Rating Upgraded by Guggenheim

Guggenheim upgraded Corbus Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday...

Corbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on Tuesday

Corbus Pharmaceuticals (NASDAQ:CRBP) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-5-corbus-pharmaceuticals-holdings-inc-stock...

Corbus Pharmaceuticals (NASDAQ:CRBP) Share Price Crosses Above Fifty Day Moving Average   - Should You Sell?

Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Cross Above 50-Day Moving Average - Should You Sell...

Corbus Pharmaceuticals (NASDAQ:CRBP) Upgraded by Wall Street Zen to "Sell" Rating

Wall Street Zen raised shares of Corbus Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Saturday...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the ten research firms that are presently covering the...

Corbus Pharmaceuticals Holdings, Inc. $CRBP Stock Holdings Lifted by Aberdeen Group plc

Aberdeen Group plc lifted its position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 602.2% during the 4th quarter, according to the company in its most recent disclosure...

Corbus Pharma Aligns With FDA On Registration Path For CRB-701 In HNSCC And Cervical Cancer

(RTTNews) - Corbus Pharmaceuticals Holdings, Inc. (CRBP), a clinical-stage company, Tuesday announced that it broadly aligned with the FDA on the registration path for CRB-701, a highly stable Nectin-4 targeting ADC, in head and neck squamous cell carcinoma (HNSCC) and cervical c...

Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Crosses Above 50-Day Moving Average - Time to Sell?

Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Pass Above 50 Day Moving Average - What's Next...

HC Wainwright Issues Negative Forecast for CRBP Earnings

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Research analysts at HC Wainwright dropped their Q1 2026 earnings estimates for shares of Corbus Pharmaceuticals in a research...

How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33%

The mean of analysts' price targets for Corbus Pharmaceuticals (CRBP) points to a 318.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

CRBPCorbus Pharmaceuticals Holdings Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRBP News